Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jerry W who wrote (7114)	3/30/1998 9:18:00 PM
From: John Mattessich	Read Replies (1) \| Respond to of 8116

Scanning thru the D/M News, I see that D/M named a new president of their Radiopharmaceuticals Division. A Mr. Richard R. Dolighan, who was previously Group Vice Pres. and GM, NA for ICN Pharm., Inc. Excerpt from the 3/11/98 press release : "Formed in 1991 as a partnership between DuPont (NYSE:DD) and Merck & Co., Inc. (NYSE:MRK), DuPont Merck is a leader in radiopharmaceuticals, with a broad product line that includes Cardiolite(R), Mariluma (TM), Quadramet (R), and I.V. Persantine(R)." That's tow mentions from D/M press releases in the past two weeks.

To: Jerry W who wrote (7114)	3/31/1998 5:48:00 PM
From: Andriy Turhovach	Read Replies (1) \| Respond to of 8116

"Cytogens PR people don't have to put out anything" Of course they don't. They don't have to do a bloody thing except sit around with their digits buried deep in dark places. We've come to expect that from them, haven't we??? That's not the point JW. Here is some damn good news for a change, why not capitalize on it??? They're staring a gift horse in the face and not doing anything with it. I apologize for the vehemence, but this is just a continued example of the total incompetence of current management.